CRMD
Income statement / Annual
Last year (2023), CorMedix Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, CorMedix Inc.'s net income was -$46.34 M.
See CorMedix Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00 |
$65,408.00 |
$190,936.00 |
$239,231.00 |
$283,266.00 |
$429,797.00 |
$329,327.00 |
$224,105.00 |
$210,130.00 |
$189,274.00 |
| Cost of Revenue |
$205,562.00
|
$3,734.00
|
$148,938.00
|
$204,846.00
|
$373,234.00
|
$396,786.00
|
$114,964.00
|
$366,673.00
|
$318,718.00
|
$445,799.00
|
| Gross Profit |
-$205,562.00
|
$61,674.00
|
$41,998.00
|
$34,385.00
|
-$89,968.00
|
$33,011.00
|
$214,363.00
|
-$142,568.00
|
-$108,588.00
|
-$256,525.00
|
| Gross Profit Ratio |
0
|
0.94
|
0.22
|
0.14
|
-0.32
|
0.08
|
0.65
|
-0.64
|
-0.52
|
-1.36
|
| Research and Development Expenses |
$13.16 M
|
$10.68 M
|
$13.13 M
|
$13.38 M
|
$11.05 M
|
$18.82 M
|
$24.49 M
|
$15.74 M
|
$6.28 M
|
$1.32 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.07 M
|
$8.65 M
|
$8.88 M
|
$10.26 M
|
$7.33 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$35.80 M
|
$20.01 M
|
$16.35 M
|
$13.88 M
|
$9.87 M
|
$8.07 M
|
$8.65 M
|
$8.88 M
|
$10.26 M
|
$7.33 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$48.96 M
|
$30.69 M
|
$29.48 M
|
$27.26 M
|
$20.92 M
|
$26.90 M
|
$33.14 M
|
$24.62 M
|
$16.55 M
|
$8.65 M
|
| Cost And Expenses |
$48.96 M
|
$30.69 M
|
$29.48 M
|
$27.46 M
|
$21.29 M
|
$27.29 M
|
$33.25 M
|
$24.99 M
|
$16.86 M
|
$9.09 M
|
| Interest Income |
$0.00
|
$326,016.00
|
$14,403.00
|
$116,065.00
|
$322,668.00
|
$36,618.00
|
$110,714.00
|
$126,774.00
|
$60,393.00
|
$2,714.00
|
| Interest Expense |
$0.00
|
$26,515.00
|
$15,943.00
|
$33,226.00
|
$787,488.00
|
$1,873.00
|
$5,619.00
|
$1,311.00
|
$3,964.00
|
$2,087.00
|
| Depreciation & Amortization |
$70,755.00
|
$209,038.00
|
$177,020.00
|
$143,487.00
|
$73,286.00
|
$74,218.00
|
$36,886.00
|
$25,596.00
|
$15,076.00
|
$15,074.00
|
| EBITDA |
-$48.89 M |
-$30.05 M |
-$29.38 M |
-$27.02 M |
-$20.63 M |
-$26.75 M |
-$32.97 M |
-$24.62 M |
-$18.17 M |
-$20.44 M |
| EBITDA Ratio |
0
|
-463.21
|
-154.21
|
-113.3
|
-73.02
|
-62.42
|
-99.64
|
-109.81
|
-78.9
|
-46.94
|
| Operating Income Ratio |
0
|
-468.2
|
-154.18
|
-113.78
|
-74.16
|
-62.5
|
-99.97
|
-110.49
|
-79.26
|
-47.03
|
| Total Other Income/Expenses Net |
$2.62 M
|
$336,646.00
|
-$22,827.00
|
$23,674.00
|
-$485,976.00
|
$34,566.00
|
-$85,804.00
|
$117,291.00
|
-$1.53 M
|
-$11.55 M
|
| Income Before Tax |
-$46.34 M
|
-$30.29 M
|
-$29.46 M
|
-$27.20 M
|
-$21.49 M
|
-$26.83 M
|
-$33.01 M
|
-$24.64 M
|
-$18.19 M
|
-$20.45 M
|
| Income Before Tax Ratio |
0
|
-463.05
|
-154.29
|
-113.69
|
-75.88
|
-62.42
|
-100.23
|
-109.96
|
-86.55
|
-108.06
|
| Income Tax Expense |
$0.00
|
-$585,617.00
|
-$1.25 M
|
-$5.17 M
|
-$5.06 M
|
$36,439.00
|
-$31,267.00
|
$1,311.00
|
$3,964.00
|
$2,087.00
|
| Net Income |
-$46.34 M
|
-$29.70 M
|
-$28.21 M
|
-$22.03 M
|
-$16.43 M
|
-$26.83 M
|
-$33.01 M
|
-$24.64 M
|
-$18.19 M
|
-$20.45 M
|
| Net Income Ratio |
0
|
-454.1
|
-147.75
|
-92.08
|
-58.01
|
-62.42
|
-100.23
|
-109.96
|
-86.55
|
-108.06
|
| EPS |
-0.91 |
-0.74 |
-0.75 |
-0.77 |
-0.68 |
-1.51 |
-2.99 |
-3.25 |
-2.9 |
-4.77 |
| EPS Diluted |
-0.91 |
-0.74 |
-0.75 |
-0.77 |
-0.68 |
-1.51 |
-2.99 |
-3.25 |
-2.9 |
-4.77 |
| Weighted Average Shares Out |
$50.90 M
|
$40.14 M
|
$37.61 M
|
$28.56 M
|
$24.15 M
|
$17.82 M
|
$11.03 M
|
$7.59 M
|
$6.27 M
|
$4.29 M
|
| Weighted Average Shares Out Diluted |
$50.90 M
|
$40.27 M
|
$37.67 M
|
$28.56 M
|
$24.15 M
|
$17.82 M
|
$11.03 M
|
$7.59 M
|
$6.27 M
|
$4.29 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
